Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

By F. Yakes, Jason J. Chen, Jenny Tan, K. Yamaguchi, Yongchang Shi, P. Yu, Fawn Qian, Felix Chu, F. Bentzien, B. Cancilla and 8 more. Molecular Cancer Therapeutics, 2011

1,192 citations recorded by the source corpus.

Subfields: Hepatology, Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/a3315e9117937d9f9c9c0a6cb8749298fe19d4c0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Mathias Wilhelm
2. B. Kuster
3. Huanhuan Chen
4. Li-li Zheng
5. Zhenling Liu
6. Li-Ping Sun
7. Lei Shi
8. Hannes Hahne

Citations in the corpus

• Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “2 nM), which is a bismethoxyquinoline analog (Table 1).(429,430) Because of the ability to inhibit autophosphorylation of VEGFR-2 and c-Met, cabozantinib exhibited decent anti-tumor, anti-metastatic, and anti-angiogenic activities in preclinical models.”
• The target landscape of clinical kinase drugs (2017, background): “6A) revealed that the designated MET/VEGFR inhibitors cabozantinib (approved for the treatment of medullary thyroid cancer and advanced renal cell carcinoma) (48) and golvatinib, among others, are potent inhibitors of the mutated tyrosine kinase FLT3-ITD that is involved in an aggressive form of acu”
• Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma (2018, neutral): “(%) Asia† 116 (25) 59 (25) Europe 231 (49) 108 (46) Canada and United States 108 (23) 59 (25) Australia and New Zealand 15 (3) 11 (5) ECOG performance-status score — no.”
• Cabozantinib versus everolimus in advanced renal cell carcinoma (2015, neutral): “Hypertension 122 (37) 49 (15) 23 (7) 10 (3)”